R. Manning

发表

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.

K. Anderson, S. Verselis, E. Fox, 2007, Blood.

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.

S. Treon, A. Roccaro, A. Sacco, 2006, Blood.

Characterization of familial Waldenstrom's Macroglobulinemia.

C. Morton, S. Treon, Z. Hunter, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study.

Karan P. Singh, S. Greenland, S. Treon, 2012, Cancer epidemiology.

CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.

N. Munshi, S. Treon, Z. Hunter, 2008, Blood.

Novel agents in the treatment of Waldenström's macroglobulinemia.

S. Treon, A. Roccaro, A. Sacco, 2007, Clinical lymphoma & myeloma.

Associated malignancies in patients with Waldenström's macroglobulinemia and their kin.

S. Treon, Z. Hunter, R. Ojha, 2011, Clinical lymphoma, myeloma & leukemia.

IgA and IgG hypogammaglobulinemia in Waldenström’s macroglobulinemia

S. Treon, Z. Hunter, M. Morra, 2010, Haematologica.

Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.

S. Treon, Z. Hunter, L. Ioakimidis, 2009, Clinical lymphoma & myeloma.

Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.

J. Kutok, Jiangwen Zhang, N. Munshi, 2007, Experimental hematology.

Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia

S. Verselis, E. Fox, S. Treon, 2009, British journal of haematology.

Whole Genome Sequencing Reveals a Widely Expressed Mutation (MYD88 L265P) with Oncogenic Activity in Waldenstrom's Macroglobulinemia

D. Skifter, S. Lincoln, J. Laramie, 2011 .

A Somatic Variant in MYD88 (L265P) Revealed by Whole Genome Sequencing Differentiates Lymphoplasmacytic Lymphoma From Marginal Zone Lymphomas

N. Harris, G. Pinkus, S. Rodig, 2011 .

Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.

S. Treon, Z. Hunter, L. Ioakimidis, 2012, Clinical lymphoma, myeloma & leukemia.

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.

S. Treon, A. Roccaro, A. Sacco, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab‐containing regimen

S. Treon, Z. Hunter, L. Ioakimidis, 2011, British journal of haematology.

Maintenance Rituximab is associated with improved clinical outcome in rituximab naı̈ve patients with Waldenstrom Macroglobulinaemia who respond

S. Treon, Z. Hunter, L. Ioakimidis, 2011 .

MYD88 wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival

S. Treon, Z. Hunter, J. Castillo, 2018, British journal of haematology.

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

N. Harris, D. Skifter, S. Lincoln, 2012, The New England journal of medicine.

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.

S. Treon, Z. Hunter, Guang Yang, 2014, Blood.

small somatic deletions associated with B-cell lymphomagenesis characterized by highly recurring MYD 88 and WHIM-like CXCR 4 mutations , The genomic landscape of Waldenstöm ' s Macroglobulinemia

S. Treon, Z. Hunter, Guang Yang, 2013 .

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

N. Munshi, N. Lindeman, S. Treon, 2013, Blood.

MYD 88 L 265 P in Waldenström macroglobulinemia , immunoglobulin M monoclonal gammopathy , and other B-cell lymphoproliferative disorders using conventional and quantitative allele-speci fi c polymerase chain reaction

N. Munshi, N. Lindeman, S. Treon, 2013 .

polymerase chain reaction disorders using conventional and quantitative allele-specific monoclonal gammopathy, and other B-cell lymphoproliferative MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M

N. Munshi, N. Lindeman, S. Treon, 2013 .

polymerase chain reaction disorders using conventional and quantitative allele-specific monoclonal gammopathy , and other B-cell lymphoproliferative MYD 88 L 265 P in Waldenström macroglobulinemia , immunoglobulin

N. Munshi, N. Lindeman, S. Treon, 2013 .

Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes

M. Kersten, S. Treon, H. Rennke, 2016, British journal of haematology.

Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.

S. Treon, L. Ioakimidis, R. Manning, 2011, Clinical lymphoma, myeloma & leukemia.

Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenstrom's macroglobulinemia (WM).

S. Treon, Z. Hunter, L. Ioakimidis, 2010 .

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2016, Blood.

Rituximab intolerance in patients with Waldenström macroglobulinaemia

S. Treon, Z. Hunter, J. Castillo, 2016, British journal of haematology.

Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia.

Hsiuyi Tseng, S. Rodig, S. Treon, 2011, Clinical lymphoma, myeloma & leukemia.

MYD88 mutated and wild-type Waldenström’s Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4

M. Cazzola, S. Treon, Z. Hunter, 2018, Haematologica.

Detection Of MYD88 L265P In Peripheral Blood Of Patients With Waldenström's Macroglobulinemia and IgM Monoclonal Gammopathy Of Undetermined Significance

N. Lindeman, S. Treon, Z. Hunter, 2013 .

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

N. Gray, S. Treon, Y. Tai, 2013, Blood.

Attainment of complete/very good partial response following rituximab‐based therapy is an important determinant to progression‐free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

Hsiuyi Tseng, S. Verselis, E. Fox, 2011, British journal of haematology.

Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance

N. Lindeman, S. Treon, J. Chen, 2014, Leukemia.

Clinical Characteristics and Treatment Outcome Of CNS Involvement (Bing-Neel Syndrome) In Waldenstrom’s Macroglobulinemia

A. Norden, E. Lee, S. Treon, 2013 .

Characterization of familial Waldenstrom's macroglobulinemia.

C. Lee, C. Morton, S. Treon, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Increased incidence of disease transformation and development of MDS/AML in Waldenstrom's macroglobulinemia (WM) patients treated with nucleoside analogues

S. Treon, A. Roccaro, I. Ghobrial, 2007 .

Somatic Activating Mutations In CXCR4 Are Common In Patients With Waldenstrom’s Macroglobulinemia, and Their Expression In WM Cells Promotes Resistance To Ibrutinib

S. Treon, Z. Hunter, Guang Yang, 2013 .

Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.

Hsiuyi Tseng, S. Treon, E. Hatjiharissi, 2009, Clinical lymphoma & myeloma.

Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia

S. Treon, I. Ghobrial, Z. Hunter, 2007, American journal of hematology.

Comparative response assessment by total serum IgM and IgM M-component in Waldenstrom’s macroglobulinemia.

S. Treon, Z. Hunter, L. Ioakimidis, 2012 .

Waldenström macroglobulinemia lymphoplasmacytic cells by activation of Bruton tyrosine kinase in A mutation in MYD88 (L265P) supports the survival of

N. Gray, S. Treon, Z. Hunter, 2014 .

CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.

J. Kutok, S. Treon, Y. Tai, 2006, Clinical lymphoma & myeloma.

Use of whole genome sequencing to identify highly recurrent somatic mutations in Waldenström’s macroglobulinemia.

S. Treon, Z. Hunter, Guang Yang, 2012 .

Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration.

S. Treon, Z. Hunter, B. Ciccarelli, 2013, Clinical lymphoma, myeloma & leukemia.

Microarray Analysis of the Peripheral Monocytes From Waldenstrom's Macroglobulinemia Patients Reveals a Distinct Gene Expression Profile

S. Treon, Jingrui Jiang, Z. Hunter, 2010 .

Plenary Paper

S. Treon, Z. Hunter, Guang Yang, 2014 .

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.

S. Treon, A. Roccaro, A. Sacco, 2006, Blood.

N. Munshi, N. Lindeman, S. Treon, 2013, Blood.

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2016, Blood.